Executives have met investors this week to test waters on offering that could value company at $35bn
It’s not clear whether the stars will align in the latest government attempt to boost activity in UK markets
Beijing’s securities regulator concerned about IPOs of companies with small capitalisation and weak fundamentals
Competition from Temu adds to pressure on fast-fashion group’s valuation as it seeks approval for UK listing
Glencore is considering moving its primary listing location from London to New York
Is it really all that bad out there?
Chief Gary Nagle says mining group is seeking to boost its valuation
Fast fashion group was targeting London listing in first half of 2025
Bankers expect flurry of listings on back of buoyant stock markets and easing financial conditions
Hotel room wholesaler’s float viewed as key test of European market in 2025
Demerged division will also trade in London and New York
Several Chinese companies expected to list in the territory this year as market activity revives
EQT-backed IVC Evidensia could float as soon as next year, delivering one of the Square Mile’s biggest listings for years
Valuation of up to $15bn would make it one of the biggest listings this year
Public flotations could raise more than $23bn in 2025 as local demand keeps valuations high
Amsterdam likely to be one location for spin-off of ice cream division, with London and New York also under consideration
Price reductions frequently happen but this is on another level
Pitch in poetry, execute in prose
Bankers expect territory to benefit from US-China tensions and Beijing’s capital controls
LNG exporter initially sought market value exceeding energy giant BP’s before scaling back IPO
US group to offer more common stock but cuts price range
Chinese lenders’ ultra-low pitches for CATL secondary offering reflect scarcity of business on mainland
Chief executive leaning towards New York listing, while board favours home market of London
Kestra Medical Technologies and Heartflow make non-invasive cardiac tests for patients with heart conditions
Liquidated investment firm Alcimos claims bank’s ‘inaccurate’ advice cost it millions of euros in potential fees
